J&J case: Government asks ‘victims’ to approach central or state panel

NEW DELHI: The government Tuesday issued a public notice stating that patients suffering from disability due to faulty articular surface replacement (ASR) hip implants can approach either the central expert committee or the state-level panel.

In case the affected patients intend to approach the central expert committee, they may write to the legal cell of the Central Drugs Standard Control Organisation, FDA Bhavan on Kotla Road, New Delhi.

They may send an email on legalcell@cdsco.nic.in.

If the affected patients approach the state-level committee, they may write to the concerned state drug controller who will be the member secretary of the state-level committee.

The Centre, earlier this month, constituted the central expert committee under the chairmanship of R K Arya, director of Sports Injury Centre at Safdarjung Hospital, to determine the quantum of compensation to be given to patients who have faulty hip implants, manufactured by DePuy International, a subsidiary of Johnson & Johnson.

Apart from the five-member expert panel, the Union Health Ministry has asked principle/health secretaries of all the states and the Union Territories to constitute separate committees so that they can receive such complaints from the affected patients.

The move came after a panel, constituted earlier by the Union Health Ministry to investigate complaints about articular surface replacement (ASR) hip implant devices, said in its report that the pharma giant “suppressed” facts on the harm of surgeries afterwards, which was conducted on patients in India using “faulty” hip replacement systems.

It had also suggested that the company pay compensation of around Rs 20 lakh to the affected patients. Some of the patients who had suffered due to the faulty implants had questioned the panel’s recommendation of the paltry amount, saying it was like “rubbing salt into their wounds”.

The Health Ministry, in its order dated August 30, has asked the central expert committee to submit its recommendation to the Central Drugs Standard Control Organisation (CDSCO) within 45 days of receiving recommendations from the state-level panels.

The order had said a committee under the chairmanship of Arun Kumar Aggarwal has given its report which has been accepted by the central government with certain modifications.

“Now the central government has decided to constitute a central expert committee to determine the quantum of compensation, as admissible under the law, in respect of faulty ASR hip implants manufactured by M/s DePuy International Limited, UK and implanted in India,” the had order said.

  • Related Posts

    Pain is passé in Blood Test, thanks to Metropolis’ Human Touch

    New Delhi: Blood drawing for test has really reached proverbial ant bite, thanks to introduction of innovative blood collection technology by Metropolis healthcare, India’s second largest pathology laboratory chain. First…

    60 Countries witnessed AMTZ, Seed of Global Hub of Medical Devices

    Vishakhapatnam: It could be the beginning of the end of dependence of India on imports of medical devices. Import lobby must have watched this gathering of 60 countries to witness…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt